Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-01-20
1999-02-02
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
058665471
ABSTRACT:
Methods of treating an affective disorder in an individual are disclosed. Affective disorders include major depression, melancholic and atypical subtypes, and dysthymia.
REFERENCES:
patent: 4612132 (1986-09-01), Wollenberg et al.
patent: 5552522 (1996-09-01), DiMarchi et al.
patent: 5552523 (1996-09-01), Basinski et al.
patent: 5552524 (1996-09-01), Basinski et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5668181 (1997-09-01), Youdin et al.
patent: 5756461 (1998-05-01), Stephens
patent: 5773416 (1998-06-01), Chehab
Kling, M.A., et al., "Effects of Electroconvulsive Therapy on the CRH-ACTH-Cortisol System in Melancholic Depression: Preliminary Findings," Psychopharmacology Bulletin 30(3):489-494 (1994).
Gold, P.W., et al., "Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs," Ann. N.Y. ACAD. Sci 771:716-729 (1995).
Lam, R.W. and Stewart, J.N., "The Validity of Atypical Depression in DSM-IV," Comprehensive Psychiatry 37(6):375-383 (1996).
Licinio, J., et al., "Human Leptin Levels Are Pulsatile and Inversely Related to Pituitary-Adrenal Function," Nature Medicine 3(5):575-579 (1997).
Cohen, L.J., "Rational Drug Use in the Treatment of Depression," Pharmacotherapy 17(1):45-61 (1997).
Wong, M.-L., et al, "Identification of Hypothalmic Transcripts Upregulaged by Antidepressants," Biochemical and Biophysical Research Commicutations 229:275-279 (1996).
Torpy, D.J. and Chrousos, G.P., "The Three-Way Interactions Between The Hypothalmic-Pituitary-Adrenal and Gonadal Axes and The Immune System," Bailliere's Clinical Rheumatology 10(2):181-198 (1996).
Gold, P.W., et al., "Stress System Abnormalities in Melancholic and Atypical Depression: Molecular, Pathophysiological, and Theraputic Implications," Molecular Psychiatry 1:257-264 (1996).
Licinio, J. and Gold, P.W., "Role of Corticotrophin Releasing Hormone 41 in Depressive Illness," Bailliere's Clinical Endrocrinology and Metabolism 5(1):51-58 (1991).
Gold, P.W., et al., "Clinical and Biochemical Manifestations of Depression: Relation to the Neurobiology of Stress (Second of Two Parts)," The New England Journal of Medicine 319(7):413-420 (1988).
Gold, P.W., et al., "Clinical and Biochemical Manifestations of Depression: Relation to the Neurobiology of Stress (First of Two Parts)," The New England Journal of Medicine 319(6):348-353 (1988).
Licinio, J., et al., "Synchronicity of Frequently Sampled, 24-h Concentrations of Circulating Leptin, Luteinizing Hormone, and Estradiol in Healthy Women," Proc. Natl. Acad. Sci. USA 95:2541-2546 (1988).
Deuschle, M., et al., "Plasma Leptin in Depressed Patients and Health Controls," Horm. Metab. Res. 28:714-717 (1996).
Comings, D.E., et al., "Genetic Variants of the Human Obesity (OB) Gene: Association With Body Mass Index in Young Women, Psychiatric Symptoms, and Interaction With the Dopamine D.sub.2 Receptor (DRD2) Gene," Molecular Psychiatry 1:325-335 (1996).
Hagerty, B.M., "Advances in Understanding Major Depressive Disorder," Journal of Psychosocial Nursing 33(11):27-34 (1995).
Dorn, L.D., et al., "Psychopathology in Patients With Endogenous Cushing's Syndrome: `Atypical` or Melancholic Features," Clinical Endocrinology 43:433-442 (1995).
Nemeroff, C.B., "The Corticotropin-Releasing Factor (CRF) Hypothesis of Depression: New Findings and New Directions," Molecular Psychiatry 1:336-342 (1996).
Gold, P.W., et al., "Responses to Corticotropin-Releasing Hormone in the Hypercortisolism of Depression and Cushing's Disease," N.E. J. of Medicine, 314(21):1329-1335 (1986).
Schwartz, M.W., et al., "Cerebrospinal Fluid Leptin Levels: Relationship to the Plasma Levels and to Adiposity in Humans," Nature, 2(5):589-593 (1996).
Vale, W., et al., "Characterization of a 41-Residue Ovine Hypothalamic Peptide That Stimulates Secretion of Corticotropin and .beta.-Endorphin," Science, 213:1394--1397 (1981).
"Drug Treatment of Disorders of Mood." In The Pharmacological Basis of Therapeutics, Eighth Edition, Goodman and Gillman's, eds. (NY: Pergamon Press), p. 422 (1990).
"Mood Disorders." In Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, American Psychiatric Association, eds. (D.C.: American Psychiatric Association) pp. 317-391 (1994).
De Castro Paixao Julio Licinio
Flier Jeffrey S.
Gold Philip W.
Wong Ma-Li
Beth Israel Deaconess Medical Center
Henley III Raymond
LandOfFree
Methods of neuroendocrine regulation of affective disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of neuroendocrine regulation of affective disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of neuroendocrine regulation of affective disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1117500